Drug updated on 12/11/2024
| Dosage Form | Injection (intramuscular; 0.5 mL) |
| Drug Class | Vaccines |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F
- Indicated for active immunization for the prevention of otitis media caused by S
- pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F
- No otitis media efficacy data are available for serotypes 1, 3, 5, 6A, 7F, and 19A
- Indicated for active immunization for the prevention of invasive disease caused by S
- pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, in children 6 years through 17 years of age (prior to the 18th birthday)
- Indicated for active immunization for the prevention of pneumonia and invasive disease caused by S
- pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, in adults 18 years of age and older
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- PCV (pneumococcal conjugate vaccines)13 resulted in significantly higher serotype-specific immunoglobulin G (IgG) responses compared to PCV10 for serotypes 4, 9V, and 23F, with geometric mean ratios ranging from 1.14- to 1.54-fold one month after the primary vaccination series in children under 2 years.
- The relative risk of seroinfection was lower for PCV13 compared to PCV10 for serotypes 4, 6B, 9V, 18C, and 23F prior to the booster dose, with a two-fold increase in antibody level after primary vaccination linked to a 54% reduction in seroinfection risk (relative risk (RR) 0.46, 95% confidence interval (CI) 0.23-0.96).
- PCV13 demonstrated improved effectiveness outcomes over PCV10 in terms of increased IgG responses and reduced seroinfection risk for specific serotypes in children under 2 years.
- There is no safety information available in the reviewed studies.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Prevnar 13 (pneumococcal 13-valent conjugate vaccine) Prescribing Information. | 2019 | Pfizer Inc., New York, NY |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data | 2023 | EClinicalMedicine |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Pneumococcal vaccine for adults aged ≥19 years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023 | 2023 | Morbidity and Mortality Weekly Report |